Equity Overview
Price & Market Data
Price: $7.93
Daily Change: -$0.29 / 3.66%
Range: $7.27 - $8.12
Market Cap: $172,048,480
Volume: 43,437
Performance Metrics
1 Week: 13.29%
1 Month: -15.82%
3 Months: -43.68%
6 Months: -43.68%
1 Year: -43.68%
YTD: -44.58%
Company Details
Employees: 22
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation. It also developing ARD-201, which is in Phase I clinical trial for the treatment of obesity. The company was incorporated in 2017 and is based in San Diego, California.